Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb.

Karl J Hale; S. Manaviazar; L. Lazarides; J. George; M.A. Walters; J. Cai; V.M. Delisser; G.S. Bhatia; S.A. Peak; S.M. Dalby; A. Lefranc; Y.P. Chen; A.W. Wood; Paul Crowe; Pauline Erwin; Mohamed El-Tanani

doi:10.1021/ol802818f

Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb.

Karl J Hale, S. Manaviazar, L. Lazarides, J. George, M.A. Walters, J. Cai, V.M. Delisser, G.S. Bhatia, S.A. Peak, S.M. Dalby, A. Lefranc, Y.P. Chen, A.W. Wood, Paul Crowe, Pauline Erwin, Mohamed El-Tanani

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

The synthesis of three potent new antitumor agents is described: the A83586C-citropeptin hybrid (1), the A83586C-GE3 hybrid (2), and l-Pro-A83586C (3). Significantly, compounds 1 and 2 function as highly potent inhibitors of ß-catenin/TCF4 signaling within cancer cells, while simultaneously downregulating osteopontin (Opn) expression. A83586C antitumor cyclodepsipeptides also inhibit E2F-mediated transcription by downregulating E2F1 expression and inducing dephosphorylation of the oncogenic hyperphosphorylated retinoblastoma protein (pRb).

Original language	English
Pages (from-to)	737-740
Number of pages	4
Journal	Organic Letters
Volume	11
Issue number	3
DOIs	https://doi.org/10.1021/ol802818f
Publication status	Published - 05 Feb 2009

ASJC Scopus subject areas

Biochemistry
Organic Chemistry
Physical and Theoretical Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/ol802818f

Cite this

Hale, K. J., Manaviazar, S., Lazarides, L., George, J., Walters, M. A., Cai, J., Delisser, V. M., Bhatia, G. S., Peak, S. A., Dalby, S. M., Lefranc, A., Chen, Y. P., Wood, A. W., Crowe, P., Erwin, P., & El-Tanani, M. (2009). Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb. Organic Letters, 11(3), 737-740. https://doi.org/10.1021/ol802818f

@article{f405b186d45d4e4c892cb9b5b4b9e203,

title = "Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb.",

abstract = "The synthesis of three potent new antitumor agents is described: the A83586C-citropeptin hybrid (1), the A83586C-GE3 hybrid (2), and l-Pro-A83586C (3). Significantly, compounds 1 and 2 function as highly potent inhibitors of {\ss}-catenin/TCF4 signaling within cancer cells, while simultaneously downregulating osteopontin (Opn) expression. A83586C antitumor cyclodepsipeptides also inhibit E2F-mediated transcription by downregulating E2F1 expression and inducing dephosphorylation of the oncogenic hyperphosphorylated retinoblastoma protein (pRb).",

author = "Hale, {Karl J} and S. Manaviazar and L. Lazarides and J. George and M.A. Walters and J. Cai and V.M. Delisser and G.S. Bhatia and S.A. Peak and S.M. Dalby and A. Lefranc and Y.P. Chen and A.W. Wood and Paul Crowe and Pauline Erwin and Mohamed El-Tanani",

year = "2009",

month = feb,

day = "5",

doi = "10.1021/ol802818f",

language = "English",

volume = "11",

pages = "737--740",

journal = "Organic Letters",

issn = "1523-7060",

publisher = "American Chemical Society",

number = "3",

}

Hale, KJ, Manaviazar, S, Lazarides, L, George, J, Walters, MA, Cai, J, Delisser, VM, Bhatia, GS, Peak, SA, Dalby, SM, Lefranc, A, Chen, YP, Wood, AW, Crowe, P , Erwin, P & El-Tanani, M 2009, 'Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb.', Organic Letters, vol. 11, no. 3, pp. 737-740. https://doi.org/10.1021/ol802818f

TY - JOUR

T1 - Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb.

AU - Hale, Karl J

AU - Manaviazar, S.

AU - Lazarides, L.

AU - George, J.

AU - Walters, M.A.

AU - Cai, J.

AU - Delisser, V.M.

AU - Bhatia, G.S.

AU - Peak, S.A.

AU - Dalby, S.M.

AU - Lefranc, A.

AU - Chen, Y.P.

AU - Wood, A.W.

AU - Crowe, Paul

AU - Erwin, Pauline

AU - El-Tanani, Mohamed

PY - 2009/2/5

Y1 - 2009/2/5

N2 - The synthesis of three potent new antitumor agents is described: the A83586C-citropeptin hybrid (1), the A83586C-GE3 hybrid (2), and l-Pro-A83586C (3). Significantly, compounds 1 and 2 function as highly potent inhibitors of ß-catenin/TCF4 signaling within cancer cells, while simultaneously downregulating osteopontin (Opn) expression. A83586C antitumor cyclodepsipeptides also inhibit E2F-mediated transcription by downregulating E2F1 expression and inducing dephosphorylation of the oncogenic hyperphosphorylated retinoblastoma protein (pRb).

AB - The synthesis of three potent new antitumor agents is described: the A83586C-citropeptin hybrid (1), the A83586C-GE3 hybrid (2), and l-Pro-A83586C (3). Significantly, compounds 1 and 2 function as highly potent inhibitors of ß-catenin/TCF4 signaling within cancer cells, while simultaneously downregulating osteopontin (Opn) expression. A83586C antitumor cyclodepsipeptides also inhibit E2F-mediated transcription by downregulating E2F1 expression and inducing dephosphorylation of the oncogenic hyperphosphorylated retinoblastoma protein (pRb).

UR - http://www.scopus.com/inward/record.url?scp=60849096395&partnerID=8YFLogxK

U2 - 10.1021/ol802818f

DO - 10.1021/ol802818f

M3 - Article

C2 - 19175352

SN - 1523-7060

VL - 11

SP - 737

EP - 740

JO - Organic Letters

JF - Organic Letters

IS - 3

ER -

Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb.

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this